Human ROR2/NTRKR2 Protein
Catalog No: ROR2-HF001
- Species
- Human
- Expression System
- HEK293
- Tag
- an hFc (IgG1)
- Activity
- Activity verified
Product overview
Recombinant Human ROR2/NTRKR2 Protein is expressed in HEK293 cells with an hFc (IgG1) tag at the C-terminus. It contains amino acid residues Glu34-Gly403 (accession: A1L4F5).
Product Details
- Molecular Aliases
- BDB; BDB1; NTRKR2; ROR2
- Protein Length
- Glu34-Gly403
- Expression System
- HEK293
- Theoretical Molecular Weight
- The protein has a predicted MW of 68 kDa. Due to glycosylation, the protein migrates to 80-110 kDa based on Bis-Tris PAGE result.
- Purity
- > 95% as determined by Bis-Tris PAGE > 95% as determined by HPLC
- Endotoxin
- Less than 1 EU per μg by the LAL method.
- Buffer / Formulation
- Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
- State
- Lyophilized
- Storage Conditions
- -20 to -80°C for 24 months as supplied from date of receipt. -80°C for 3 months after reconstitution. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
- Reconstitution Advice
- Dissolve the lyophilized protein in distilled water. Please refer to the Certificate of Analysis for detailed instructions.
Data Display
Human ROR2 on Bis-Tris PAGE under reduced conditions. The purity is greater than 95%.
The purity of Human ROR2 is greater than 95% as determined by SEC-HPLC.
Immobilized Human ROR2, hFc Tag at 1μg/ml (100μl/well) on the plate. Dose response curve for Biotinylated Anti-ROR2 Antibody, hFc Tag with the EC50 of 20.9ng/ml determined by ELISA.
Background
ROR2 (Receptor Tyrosine Kinase-like Orphan Receptor 2) is a member of the ROR family of receptor tyrosine kinases and is important for skeletal development, including bone and cartilage formation, as well as for the development of the central nervous system. Mature human ROR2 contains a 369 amino acid (aa) extracellular domain (ECD) and a 518 aa cytoplasmic tail containing an tyrosine kinase domain.
References
- Debebe Z, Rathmell W K. Ror2 as a Therapeutic Target in Cancer[J]. Pharmacology & Therapeutics, 2015, 150:143-148.
Have questions about this product?
Our technical team can help with product selection, application questions and order support.